Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hydroxypropyl betadex - Cyclo Therapeutics

Next Previous
Drug Profile

Hydroxypropyl betadex - Cyclo Therapeutics

Alternative Names: HP-Beta-CD - Cyclo Therapeutics; HP-β-CD - Cyclo Therapeutics; Hydroxypropyl-beta-cyclodextrin - Cyclo Therapeutics; Trappsol Cyclo; Trappsol® Hydroxypropyl Beta Cyclodextrin-Endotoxin Controlled (THPB-EC) grade - Cyclo Therapeutics

Latest Information Update: 26 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CTD Holdings
  • Developer Cyclo Therapeutics
  • Class Anti-inflammatories; Antidementias; Antivirals; Beta-Cyclodextrins; Ethers; Peripheral vasodilators; Urologics; Vascular disorder therapies
  • Mechanism of Action Binding agents; Cholesterol modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Niemann-Pick disease type C
  • New Molecular Entity No

Highest Development Phases

  • Phase III Niemann-Pick disease type C
  • Phase II Alzheimer's disease
  • No development reported Diabetic nephropathies; Peripheral arterial disorders; Viral infections

Most Recent Events

  • 14 Mar 2024 Cyclo Therapeutics has patent protection for hydroxypropyl betadex in the US
  • 29 Jan 2024 Cyclo Therapeutics receives patent allowance for Hydroxypropyl betadex in the US
  • 14 Dec 2023 Cyclo Therapeutics conducts a Type C meeting with the US FDA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top